Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formulary decisions rely more on clinical profiles than cost efficacy, ex-Aetna VP McGivney tells DIA.

Executive Summary

MANAGED CARE FORMULARY DECISIONS RELY PRIMARILY ON CLINICAL ADVANTAGE determinations between products and only secondarily on cost-effectiveness data, former Aetna VP-Clinical Coverage Policy Bill McGivney (National Comprehensive Cancer Network) maintained at the Drug Information Association's annual meeting in Montreal on June 25. "It is only when there is no clinical advantage that can be discerned that we get down to explicit considerations of cost," McGivney said. "In terms of formal, systematic application of cost-effectiveness analysis in the managed care setting, it really hasn't happened."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel